Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm.; SUBCELLULAR LOCATION: Isoform 1: Cell membrane. Cytoplasmic vesicle. Note=Localized to the plasma membrane and intracellular vesicles, including late endosomal vesicles.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm Note=May be cytoplasmic and is not localized to membranes. |
Domain |
PF00017 SH2 domain PF00018 SH3 domain |
Function |
Adapter protein, which negatively regulates T-cell receptor (TCR) signaling. Inhibits T-cell antigen-receptor induced activation of nuclear factor of activated T-cells. May act by linking signaling proteins such as ZAP70 with CBL, leading to a CBL dependent degradation of signaling proteins. |
Biological Process |
GO:0002250 adaptive immune response GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002695 negative regulation of leukocyte activation GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0007159 leukocyte cell-cell adhesion GO:0019722 calcium-mediated signaling GO:0019724 B cell mediated immunity GO:0019932 second-messenger-mediated signaling GO:0030522 intracellular receptor signaling pathway GO:0042110 T cell activation GO:0042113 B cell activation GO:0050848 regulation of calcium-mediated signaling GO:0050849 negative regulation of calcium-mediated signaling GO:0050851 antigen receptor-mediated signaling pathway GO:0050864 regulation of B cell activation GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0050869 negative regulation of B cell activation GO:0051249 regulation of lymphocyte activation GO:0051250 negative regulation of lymphocyte activation GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071593 lymphocyte aggregation GO:1902532 negative regulation of intracellular signal transduction |
Molecular Function |
GO:0005070 SH3/SH2 adaptor activity GO:0030674 protein binding, bridging GO:0035591 signaling adaptor activity GO:0047485 protein N-terminus binding GO:0060090 binding, bridging |
Cellular Component |
GO:0005770 late endosome GO:0010008 endosome membrane GO:0044440 endosomal part |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between SLA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of SLA2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of SLA2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of SLA2 in various data sets.
|
Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLA2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of SLA2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between SLA2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | SLA2 |
Name | Src-like-adaptor 2 |
Aliases | FLJ21992; SLAP-2; C20orf156; SLAP2; Src-like adapter protein-2; modulator of antigen receptor signaling; Src ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting SLA2 collected from DrugBank database. |
There is no record. |